Falla cardíaca aguda

Juan Manuel Senior

Resumen


Introducción: se han considerado como falla cardíaca aguda el inicio rápido de síntomas sugestivos de disfunción ventricular o el cambio significativo de estos en un paciente previamente diagnosticado con la enfermedad, que usualmente requiere atención urgente y tratamiento hospitalario.

Metodología: para la realización de la guía de práctica clínica (GPC) basada en la evidencia se siguieron los pasos definidos en la Guía Metodológica para la Elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud del Ministerio de Salud y Protección Social de Colombia.

Resultados: se establecen las recomendaciones de tratamiento de la falla cardíaca aguda.

Conclusión: las metas del tratamiento de la falla cardíaca aguda están dirigidas a la rápida compensación del paciente para introducir posteriormente las terapias que han demostrado cambiar la morbilidad y la mortalidad a largo plazo.


Palabras clave


Guía; Insuficiencia Cardíaca; Cardiotónicos

Texto completo:

PDF

Referencias


(1.) Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003 May;41(10):1797-804.

(2.) Mariani J, Macchia A, Belziti C, Deabreu M, Gagliardi J, Doval H, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: a meta-analysis of randomized controlled trials. J Card Fail. 2011 Oct;17(10):850-9. DOI 10.1016/j.cardfail.2011.05.010.

(3.) Williams JW Jr, Cox CE, Hargett CW, Gilstrap DL, Castillo CE, Govert JA, et al. Noninvasive Positive-Pressure Ventilation (NPPV) for Acute Respiratory Failure. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. (Comparative Effectiveness Reviews, No. 68)

(4.) Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010 May;152(9):590-600. DOI 10.7326/0003-4819-152-9-201005040-00009. Erratum in: Ann Intern Med. 2010 Jul;153(1):67. Ann Intern Med. 2010 Aug;153(4):280.

(5.) Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013 May;(5):CD005351. DOI 10.1002/14651858.CD005351.pub3.

(6.) Vital FM, Saconato H, Ladeira MT, Sen A, Hawkes CA, Soares B, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev. 2008 Jul;(3):CD005351. DOI 10.1002/14651858.CD005351. pub2. Update in: Cochrane Database Syst Rev. 2013;5:CD005351.

(7.) National Clinical Guideline Centre (UK). Acute Heart Failure: Diagnosing and Managing [Internet]. London: National Institute for Health and Care Excellence (UK); 2014 Oct. [cited 2016 May 2]. Available from: https://www.nice.org.uk/guidance/cg187

(8.) Agmy GM, Ghanem MK. CPAP versus BiPAP in acute cardiogenic pulmonary edema: experience with 129 patients (NCT00912158) 2009 [Internet]. [cited 2015 Nov 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT00912158

(9.) Bersten AD, Holt AW, Vedig AE, Skowronski GA, Baggoley CJ. Treatment of severe cardiogenic pulmonary

edema with continuous positive airway pressure delivered by face mask. N Engl J Med. 1991 Dec;325(26):1825-30.

(10.) Crane SD, Elliott MW, Gilligan P, Richards K, Gray AJ. Randomised controlled comparison of continuous positive airways pressure, bilevel non-invasive ventilation, and standard treatment in emergency department patients with acute cardiogenic pulmonary oedema. Emerg Med J. 2004 Mar;21(2):155-61.

(11.) Delclaux C, L’Her E, Alberti C, Mancebo J, Abroug F, Conti G, et al. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: A randomized controlled trial. JAMA. 2000 Nov;284(18):2352-60.

(12.) Ducros L, Logeart D, Vicaut E, Henry P, Plaisance P, Collet JP, et al. CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study. Intensive Care Med. 2011 Sep;37(9):1501-9. DOI 10.1007/s00134-011-2311-4.

(13.) Ferrer M, Esquinas A, Leon M, Gonzalez G, Alarcon A, Torres A. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med. 2003 Dec;168(12):1438-44.

(14.) Frontin P, Bounes V, Houzé-Cerfon CH, Charpentier S, Houzé-Cerfon V, Ducassé JL. Continuous positive airway pressure for cardiogenic pulmonary edema: a randomized study. Am J Emerg Med. 2011 Sep;29(7):775-81. DOI 10.1016/j.ajem.2010.03.007.

(15.) Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon S, et al. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess. 2009 Jul;13(33):1-106. DOI 10.3310/hta13330.

(16.) Kelly CA, Newby DE, McDonagh TA, Mackay TW, Barr J, Boon NA, et al. Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J. 2002 Sep;23(17):1379-86.

(17.) L’Her E, Duquesne F, Girou E, de Rosiere XD, Le Conte P, Renault S, et al. Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema patients. Intensive Care Med. 2004 May;30(5):882-8.

(18.) Levitt MA. A prospective, randomized trial of BiPAP in severe acute congestive heart failure. J Emerg Med. 2001 Nov;21(4):363-9.

(19.) Lin M, Yang YF, Chiang HT, Chang MS, Chiang BN, Cheitlin MD. Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short-term results and long-term follow-up. Chest. 1995 May;107(5):1379-86.

(20.) Masip J, Betbesé AJ, Páez J, Vecilla F, Cañizares R, Padró J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema: a randomised trial.

Lancet. 2000 Dec;356(9248):2126-32.

(21.) Nava S, Carbone G, DiBattista N, Bellone A, Baiardi P, Cosentini R, et al. Noninvasive ventilation in cardiogenic pulmonary edema: a multicenter randomized trial. Am J Respir Crit Care Med. 2003 Dec;168(12):1432-7.

(22.) Park M, Lorenzi-Filho G, Feltrim MI, Nazário Viecili PR, Sangean MC, Volpe M, et al. Oxygen therapy, continuous positive airway pressure, or noninvasive bilevel positive pressure ventilation in the treatment of acute cardiogenic pulmonary edema. Arq Bras Cardiol. 2001 Mar;76(3):226-30. DOI 10.1590/S0066-782X2001000300005.

(23.) Park M, Sangean MC, Volpe Mde S, Feltrim MI, Nozawa E, Leite PF, et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med. 2004 Dec;32(12):2407-15.

(24.) Räsänen J, Heikkilä J, Downs J, Nikki P, Väisänen I, Viitanen A. Continuous positive airway pressure by face mask in acute cardiogenic pulmonary edema. Am J Cardiol. 1985 Feb;55(4):296-300.

(25.) Takeda S, Nejima J, Takano T, Nakanishi K, Takayama M, Sakamoto A, et al. Effect of nasal continuous positive airway pressure on pulmonary edema complicating acute myocardial infarction. Jpn Circ J. 1998 Aug;62(8):553-8.

(26.) Takeda S, Takano T, Ogawa R. The effect of nasal continuous positive airway pressure on plasma endothelin-1 concentrations in patients with severe cardiogenic pulmonary edema. Anesth Analg. 1997 May;84(5):1091-6.

(27.) Weitz G, Struck J, Zonak A, Balnus S, Perras B, Dodt C. Prehospital noninvasive pressure support ventilation for acute cardiogenic pulmonary edema. Eur J Emerg Med. 2007 Oct;14(5):276-9.

(28.) Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008 Jul;359(2):142-51. DOI 10.1056/NEJMoa0707992.

(29.) Goodacre S, Gray A, Newby D, Dixon S, Masson M, Sampson F, et al. Health utility and survival after hospital admission with acute cardiogenic pulmonary oedema. Emerg Med J. 2011 Jun;28(6):477-82. DOI 10.1136/emj.2009.089631.

(30.) Plaisance P, Pirracchio R, Berton C, Vicaut E, Payen D. A randomized study of out-of-hospital continuous positive airway pressure for acute cardiogenic pulmonary oedema: physiological and clinical effects. Eur Heart J. 2007 Dec;28(23):2895-901.

(31.) Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol. 2000 Sep;36(3):832-7.

(32.) Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 Feb;113(6):e85-151. Erratum in: Circulation. 2006 Apr;113(14):e696. Circulation. 2006 Dec 5;114(23):e630.

(33.) Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF Jr, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004 Dec;10(6):460-6.

(34.) Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003 Nov;290(19):2581-7.

(35.) Felker GM, O’Connor CM, Braunwald E; Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009 Jan;2(1):56-62. DOI 10.1161/CIRCHEARTFAILURE.108.821785.

(36.) Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999 Sep;100(12):1311-5.

(37.) Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006 Jun;27(12):1431-9.

(38.) Montera MW, Pereira SB, Colafranceschi AS, Rodrigues Dde A, Tinoco EM, Rocha RM, et al. Sumário de atualização da II Diretriz Brasileira de Insuficiência Cardíaca Aguda 2009/2011. Arq Bras Cardiol. 2012;98(5):375-83.

(39.) Bocchi EA, Marcondes-Braga FG, Bacal F, Ferraz AS, Albuquerque D, Rodrigues Dde A, et al. [Updating of the Brazilian guideline for chronic heart failure - 2012]. Arq Bras Cardiol. 2012 Jan;98(1 Suppl 1):1-33. Portuguese.

(40.) McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Holder E, et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol. 2011 May-Jun;27(3):319-38. DOI 10.1016/j.cjca.2011.03.011.

(41.) McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol. 2013 Feb;29(2):168-81. DOI 10.1016/j.cjca.2012.10.007.

(42.) Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ; National Heart Foundation of Australia; et al. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust. 2011 Apr;194(8):405-9.

(43.) McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33(14):1787-847. DOI 10.1093/eurheartj/ehs104. Erratum in: Eur Heart J. 2013 Jan;34(2):158.

(44.) Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194. DOI 10.1016/j.cardfail.2010.04.004.

(45.) Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct;128(16):1810-52. DOI 10.1161/CIR.0b013e31829e8807.

(46.) Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724-9.

(47.) Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985 Jul;103(1):1-6.

(48.) Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17-22.

(49.) Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002 Mar;105(11):1348-53. Erratum in: Circulation 2002 Sep;106(13):1743.

(50.) Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008 Jan;51(3):300-6. DOI 10.1016/j.jacc.2007.09.043.

(51.) Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004 Feb;147(2):331-8.

(52.) Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007 Oct;9(10):1064-9.

(53.) Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006 Jun5;97(12):1759-64.

(54.) Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008 Jun;14(5):388-93. DOI 10.1016/j.cardfail.2008.01.015.

(55.) Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997 Aug;80(4):519-22.

(56.) Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004 Jan;43(1):61-7.

(57.) Aaser E, Gullestad L, Tølløfsrud S, Lundberg J, Hall C, Djøseland O, et al. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest. 1997 Jul;57(4):361-7.

(58.) Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O’Connor CM. Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010 Jun;105(12):1794-7. DOI 10.1016/j.amjcard.2010.01.355.

(59.) Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996 Aug;28(2):376-82.

(60.) Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar;364(9):797-805. DOI 10.1056/NEJMoa1005419.

(61.) Lahav M, Regev A, Ra’anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992 Sep;102(3):725-31.

(62.) Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003 Mar;145(3):459-66.

(63.) Parrinello G, Paterna S, Di Pasquale P, Torres D, Mezzero M, Cardillo M, et al. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure. J Card Fail. 2011 Apr;17(4):331-9. DOI 10.1016/j.cardfail.2010.11.003.

(64.) Pivac N, Rumboldt Z, Sardelić S, Bagatin J, Polić S, Ljutić D, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res. 1998;18(3):121-8.

(65.) Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JE, Van Bakel AB. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010 Mar;16(3):188-93. DOI 10.1016/j.cardfail.2009.11.005.

(66.) Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus highdose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005 Jun;45(12):1997-2003.

(67.) Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;(1):CD003178. Update in: Cochrane Database Syst Rev. 2005;(3):CD003178.

(68.) Wu MY, Chang NC, Su CL, Hsu YH, Chen TW, Lin YF, et al. Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. J Crit Care. 2014 Feb;29(1):2-9. DOI 10.1016/j.jcrc.2013.10.009.

(69.) Costanzo MR, Johannes RS, Pine M, Gupta V, Saltzberg M, Hay J, et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J. 2007 Aug;154(2):267-77.

(70.) Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013 Aug;(8):CD005151. DOI 10.1002/14651858.CD005151.pub2.

(71.) Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008 Jul;52(3):200-7. DOI 10.1016/j.jacc.2008.02.083.

(72.) De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 Mar;362(9):779-89. DOI 10.1056/NEJMoa0907118.

(73.) Havel C, Arrich J, Losert H, Gamper G, Müllner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2011 May;(5):CD003709. DOI 10.1002/14651858.CD003709.pub3. Update in: Cochrane Database Syst Rev. 2016;2:CD003709.

(74.) Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med. 2008 Jan;36(1 Suppl):S106-11. DOI 10.1097/01.CCM.0000296273.72952.39.

(75.) Ruiz-Laiglesia FJ, Camafort-Babkowski M. [Vasoactive and inotropic drugs in acute heart failure]. Med Clin (Barc). 2014 Mar;142 Suppl 1:49-54. DOI 10.1016/S0025-7753(14)70083-1. Spanish.

(76.) Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol. 2014 May;63(20):2069-78. DOI 10.1016/j.jacc.2014.01.016.

(77.) Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al. Effects of levosimendan on mortality and hospitalization. A metaanalysis of randomized controlled studies. Crit Care Med. 2012 Feb;40(2):634-46. DOI 10.1097/CCM.0b013e318232962a.

(78.) Huang X, Lei S, Zhu MF, Jiang RL, Huang LQ, Xia GL, et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. J Zhejiang Univ Sci B. 2013 May;14(5):400-15. DOI 10.1631/jzus.B1200290.

(79.) Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012 Mar;38(3):359-67. DOI 10.1007/s00134-011-2435-6.

(80.) Ribeiro RA, Paim Rohde LE, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arq Bras Cardiol. 2010 Aug;95(2):230-7. DOI 10.1590/S0066-782X2010005000072.

(81.) Hernández A, Miranda A, Parada A. Levosimendán disminuye la mortalidad en cirugía cardíaca: revisión sistemática y metaanálisis. Rev Esp Anestesiol Reanim. 2012 Jan;59(1):6-11. DOI 10.1016/j.redar.2012.02.001.

(82.) Retraction: De Hert SG, Lorsomradee S, vanden Eede H, Cromheecke S, Van der Linden PJ. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth 2008;22:699-705. J Cardiothorac Vasc Anesth. 2011 Oct;25(5):897.

(83.) Zairis MN, Apostolatos C, Anastasiadis P, Kouris N, Grassos H, Karidis K, et al. 273 Comparison of the effect of levosimendan, or dobutamin or placebo in chronic low output decompensated heart failure. CAlcium sensitizer or Inotrope or NOne in low output heart failure (CASINO) study. Eur J Hear Fail Suppl. 2004 Jun;3(S1):66. DOI 10.1016/S1567-4215(04)90194-4.

(84.) Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012 Mar;38(3):359-67. DOI 10.1007/s00134-011-2435-6.

(85.) Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation. 1977 Sep;56(3):468-72.

(86.) Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1980 Nov;100(5):622-30.

(87.) Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 1986 Oct;112(4):787-91.

(88.) Sindone AP, Keogh AM, Macdonald PS, McCosker CJ, Kaan AF. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J. 1997 Nov;134(5 Pt 1):889-900.

(89.) Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999 Aug;138(2 Pt 1):247-53.

(90.) Seino Y, Momomura S, Takano T, Hayakawa H, Katoh K. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Crit Care Med. 1996 Sep;24(9):1490-7.

(91.) Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 Mar;287(12):1541-7.

(92.) Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. 2003 Feb;145(2):324-9.

(93.) Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000 Nov;36(6):1903-12.

(94.) Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002 Sep;23(18):1422-32.

(95.) Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003 Jan;107(1):81-6.

(96.) Packer M, Colucci WS, Fisher L, Massie BM, Teerlink JR, Young JB, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. J Card Fail. 2003;9:S61-S.

(97.) Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006 Jan;8(1):105-10.

(98.) Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006 Jul;98(1):102-6.

(99.) Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 2006 Dec;98(12):1641-5.

(100.) Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013 May;15(5):565-72. DOI 10.1093/eurjhf/hfs215.

(101.) Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004 Jun;6(4):501-8.

(102.) Coletta AP, Cleland JG, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRINGUP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronization therapy. Eur J Heart Fail. 2004 Aug;6(5):673-6.

(103.) Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013 Apr;1(2):103-11. DOI 10.1016/j.jchf.2012.12.004.

(104.) Follath F, Hinkka S, Jäger D, Just H, Mitrovic V, Papp JG, et al. Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol. 1999 Jun;83(12):21-5. DOI 10.1016/S0002-9149(99)00314-8.

(105.) Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul;360(9328):196-202.

(106.) Duygu H, Nalbantgil S, Ozerkan F, Zoghi M, Akilli A, Erturk U, et al. Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clin Cardiol. 2008 Dec;31(12):607-13. DOI 10.1002/clc.20332.

(107.) Samimi-Fard S, García-González MJ, Domínguez-Rodríguez A, Abreu-González P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol. 2008 Jul;127(2):284-7.

(108.) Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007 May;297(17):1883-91.

(109.) Duygu H, Turk U, Ozdogan O, Akyuz S, Kirilmaz B, Alioglu E, et al. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. Cardiovasc Ther. 2008 Fall;26(3):182-8. DOI 10.1111/j.1755-5922.2008.00050.x.

(110.) Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010 Apr;12(4):404-10. DOI 10.1093/eurjhf/hfq032.

(111.) Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB Jr. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation. 1984 Jan;69(1):113-9.

(112.) Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec;16(6):265-70. DOI 10.1111/j.1751-7133.2010.00185.x.

(113.) Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003 Mar;41(6):997-1003.

(114.) Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec;81(2-3):141-9.

(115.) Biddle TL, Benotti JR, Creager MA, Faxon DP, Firth BG, Fitzpatrick PG, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol. 1987 Jun;59(15):1345-50.

(116.) Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al. B-CONVINCED: Betablocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009 Sep;30(18):2186-92. DOI 10.1093/eurheartj/ehp323.

(117.) Gattis WA, O’Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003 Jan;91(2):169-74.

(118.) Butler J, Young JB, Abraham WT, Bourge RC, Adams KF Jr, Clare R, et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol. 2006 Jun;47(12):2462-9.

(119.) Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail. 2007 Sep;9(9):901-9.

(120.) Orso F, Baldasseroni S, Fabbri G, Gonzini L, Lucci D, D’Ambrosi C, et al. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail. 2009 Jan;11(1):77-84. DOI 10.1093/eurjhf/hfn008.

(121.) Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008 Jul;52(3):190-9. DOI 10.1016/j.jacc.2008.03.048.

(122.) Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005 Oct;294(13):1625-33.

(123.) Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PACMan): a randomised controlled trial. Lancet. 2005 Aug;366(9484):472-7.

(124.) Sotomi Y, Sato N, Kajimoto K, Sakata Y, Mizuno M, Minami Y, et al. Impact of pulmonary artery catheter on outcome in patients with acute heart failure syndromes with hypotension or receiving inotropes: from the ATTEND Registry. Int J Cardiol. 2014 Mar;172(1):165-72. DOI 10.1016/j.ijcard.2013.12.174.

(125.) Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G, et al. Impact of the pulmonary artery catheter in critically ill patients: metaanalysis of randomized clinical trials. JAMA. 2005 Oct;294(13):1664-70.

(126.) Rajaram SS, Desai NK, Kalra A, Gajera M, Cavanaugh SK, Brampton W, et al. Pulmonary artery catheters for adult patients in intensive care. Cochrane Database Syst Rev. 2013 Feb;(2):CD003408. DOI 10.1002/14651858.CD003408.pub3.


Resumen : 576 PDF : 787

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2017 Iatreia

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

Esta publicación hace parte del Sistema de Revistas de la Universidad de Antioquia
¿Quieres aprender a usar el Open Journal system? Ingresa al Curso virtual
Este sistema es administrado por el Programa Integración de Tecnologías a la Docencia
Universidad de Antioquia
Powered by Public Knowledge Project